BeiGene Q3 product revenue up 82% to $349.5M; BRUKINSA sales +136%; net loss widens

BeOne Medicines Ltd.

2022-Q3 EPS reported -$1.16 revenue$1,035,826,000

Product revenue $349.5M (+82% YoY); BRUKINSA global sales $155.5M (+136%), U.S. $108.1M (+221%).
Net loss $557.6M ($0.41/share) vs $438.1M loss prior year; includes $125.6M FX losses.
Cash $5.1B (down from $6.6B); cash used in operations $561.9M.
BRUKINSA achieved superior PFS vs ibrutinib in ALPINE final analysis; EC approved MZL; CHMP positive for CLL.
Tislelizumab China sales $128.2M (+67%); HCC trial met OS endpoint vs sorafenib.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BeOne Medicines Ltd. reported the three months ended September 30, 2022 results: revenue $387.6 million, net income net loss of $557.6 million.

Period: the three months ended September 30, 2022
Revenue: $387.6 million
Net income: net loss of $557.6 million
Result: reported results

Exact text from the filing

into the U.S. dollar negatively impacted ending cash by $62.7 million in the three months ended September 30, 2022. Revenue for the three months ended September 30, 2022 was $387.6 million, compared to $206.4 million in the same period of 2021. • Product revenue totaled $349.5 million for the three months ended September 30, 2022, compared to $192.5 million in the

View on SEC.gov

Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-22-000208

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.